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Objectives: In adults, the incidence of S. pneumoniaeinfections and the related 
mortality increase with age and co-morbidities. The Belgian Superior Health Council 
recommends use of 13-valent pneumococcal conjugate vaccine (PCV13) in adults 
with elevated risk of pneumococcal diseases. PCV13 has recently proven effica-
cious in preventing pneumococcal pneumonia and invasive pneumococcal dis-
ease (IPD) in the elderly. We investigated the cost-effectiveness of vaccinating the 
65-84 y. old cohort (n= 862,188) that suffer from co-morbidities or immunosuppres-
sion MethOds: A cohort model with a Markov-type process was developed to 
project the lifetime risks and related costs of IPD and nonbacteremic pneumococcal 
pneumonia. Input data came from various sources (literature, existing databases, 
and observational studies) and were reviewed by a panel of Belgian experts. PCV13 
effectiveness was derived from the recently published CAPiTA clinical trial results 
for the first 5 years. Protection gradually declined thereafter to zero by year 16. 
Belgian National Health perspective was taken with costs and quality-adjusted life 
years (QALYs), discounted annually by 3% and 1.5%, respectively. Sensitivity analyses 
on key parameters were performed in order to test the robustness of model find-
ings. Results: 58% vaccination coverage with PCV13 in 65-84 year olds suffering 
from co-morbidities or immunosuppression is expected to prevent 6,798 cases of 
pneumococcal disease, and 911 disease-related deaths over lifetime compared to 
no vaccination. PCV13 vaccination cost was fully offset by reduction in disease-
related costs (€ 61 million), and thus was overall cost-saving. In the one-way sensi-
tivity analysis, results were most sensitive to PCV13 price and parameters related 
to inpatient pneumonia. In probabilistic sensitivity analysis, PCV13 dominated the 
no vaccination strategy in 97% of the simulations. cOnclusiOns: PCV13 vaccina-
tion of the 65-84 year-old cohort in Belgium would prevent a substantial number 
of cases and deaths from severe pneumococcal disease and be cost-saving from a 
healthcare perpective .
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Objectives: Herpes Zoster (HZ) and its most common complication, Post-Herpetic 
Neuralgia (PHN), are painful and debilitating conditions with an important burden 
for patients and society. A live-attenuated one-dose vaccine was licensed in 2006 
for the prevention of both HZ and PHN in adults 50+ years old and is currently 
recommended and part of vaccination calendars in several countries. The objec-
tive of this study was to assess the cost-effectiveness of zoster vaccination for the 
50+ population in Portugal. MethOds: An existing European Markov cohort model 
was adapted to the Portuguese healthcare setting. Health states considered are 
healthy, HZ, PHN, healthy post-HZ and death. HZ and PHN states are further split 
by pain severity (mild, moderate or severe). According to local guidelines, the cost-
effectiveness outcomes were assessed from the societal perspective for a public 
reimbursement at 37%. Analysis comparing a HZ vaccination for adults aged ≥ 50 
years with no vaccination was done. Input data were obtained from Portuguese 
sources whenever available. Results: The strategy of vaccinating adults 50+ years 
old showed an incremental cost-effectiveness ratio of 19.625€ per quality adjusted 
life year (QALY) gained from a societal perspective. The analysis showed cost-effec-
tiveness improvement with age with an ICER in the 65+ population of 15.517€ /QALY 
from the societal perspective. The probabilistic sensitivity analyses showed that 
for high levels of certainty (95%) the ICER does not exceed 25.000€ /QALY from the 
societal perspective. cOnclusiOns: Considering the generally acceptable thresh-
old, the present cost-effectiveness analysis demonstrates that HZ vaccination for 
adults 50+ years old in Portugal is a cost-effective strategy. Vaccine reimbursement 
would provide substantial health, social and economic benefits in the Portuguese 
health care context.
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Objectives: To estimate the cost-effectiveness of three candins (anidulafungin, 
caspofungin, and micafungin) and generic fluconazole in the treatment of non-neu-
tropenic adult patients with candidemia and/or invasive candidiasis (IC) in intensive 
care units (ICU) in Spain. MethOds: A decision tree model was performed. The 
success (clinical and microbiological response) and safety (hepatic and renal adverse 
effects) of first-line treatments were obtained from meta-analyses and systematic 
reviews of clinical trials. In the case of failure, a second-line treatment (liposomal 
amphotericin B after the candins, or one of the candins after fluconazole) was 
administered. The duration of the treatments (14 days total) was established by 
IDSA guidelines. The cost of the medications and renal toxicity were considered. 
Deterministic and probabilistic sensitivity analysis using Monte Carlo simulations 
were carried out. Results: The total cost of the treatment of candidemia and/or 
invasive candidiasis with anidulafungin, caspofungin, micafungin, and flucona-
zole was € 5483, € 5968, € 6231, and € 2088, respectively. Anidulafungin was the 
dominant treatment (more effective, less expensive) compared to micafungin and 
above, and recently approved for 50 years and above. The aim of present study 
was to evaluate the cost-effectiveness of implementing HZ vaccination program 
for adults at age 50 years versus 60 years in Hong Kong from the perspective of 
society. MethOds: A Markov model was designed to compare the clinical and 
economic outcomes of a hypothetical cohort of 50-year-old adults with (1) no 
HZ vaccination, (2) vaccination at 50-year-old, and (3) vaccination at 60-year-old. 
Model inputs were retrieved from literature. HZ-associated total costs (direct and 
indirect costs) and quality-adjusted life years (QALYs) loss were outcome measures 
of the model. Sensitivity analyses were conducted to examine the robustness of 
model results. Results: In base-case analysis, the two vaccination strategies were 
more costly with less QALY loss than no vaccination. Comparing to no vaccination, 
incremental cost-effectiveness ratio (ICER) of vaccinating at 50 and 60 years old 
were HKD175,397 per QALY saved and HKD190,174 per QALY saved, respectively 
(USD1= HKD7.8). All-cause death rate and prevalence of HZ were two potential 
influential factors on the base-case results. In 10,000 Monte Carlo simulations, the 
probability of HZ vaccination at 50-year-old to be the preferred option was 98.2% 
of time, using the gross domestic product per capita in Hong Kong (HKD297,360) 
as threshold of willingness-to-pay. cOnclusiOns: HZ vaccination for adults aged 
50-year-old in Hong Kong seems to be the preferred option when compared to 
vaccination at 60-year-old and no vaccination.
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Objectives: In Germany, vaccination of infants with a 13-valent pneumococcal 
conjugate vaccine (PCV13) and of individuals > = 60 years with a 23-valent pneumo-
coccal polysaccharide vaccine (PPSV23) is recommended to prevent pneumococcal 
diseases. Recently, PCV13 was also approved for individuals > = 50 years. The study 
assesses the cost-effectiveness of four vaccination strategies targeting adults > = 60 
years in Germany: no vaccination, vaccination with PCV13 only, vaccination with 
PPSV23 only, and sequential-vaccination (PCV13+PPSV23). MethOds: A suscepti-
ble-infected-susceptible type model based on ordinary differential equations was 
developed to capture the dynamic transmission of pneumococcal carriage. The 
model compartments were further stratified by age- and pneumococcal serotype-
groups. Model parameters were either retrieved from the literature or obtained 
by fitting against local incidence data. The epidemiological impact of childhood 
PCV13-vaccination (herd and serotype replacement effects) on incidence and 
serotype mix among adults as well as components of the four adult vaccination 
strategies was implemented in the model. A health-economic model was built to 
compute the incremental cost-effectiveness ratios (ICER) per QALY using German 
cost data. The robustness of the model results was assessed through sensitivity 
analyses regarding uncertain input data. Results: In the base case, the ICER of 
PPSV23 vs. no vaccination was € 24,085/QALY. Immunization with PCV13 alone was 
dominated by PPSV23-vaccination. Sequential vaccination vs. PPSV23 vaccina-
tion resulted in € 400,528/QALY. Main reason for the higher ICERs of the latter two 
strategies was a sharp decline in PCV13-serotypes prevalence among adults as 
an indirect result of infant PCV13-vaccination. Sensitivity analyses identified the 
effectiveness of PPSV23 against non-invasive pneumococcal pneumonia to have a 
substantial impact on the model results and be a major source of uncertainty due 
to the heterogeneity in reported effectiveness/efficacy data. cOnclusiOns: From 
a health economic perspective, PPSV23 would be the preferred vaccine to be used 
for the prevention of pneumococcal disease in adults in Germany.
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Objectives: Assess the cost-effectiveness of the reinstatement (stopped in 2003) of 
an 18-month booster dose of diphtheria, tetanus and acellular pertussis (DTPa-18-
month) vaccine on the National Immunisation Program (NIP) in Australia, focusing 
on pertussis prevention. MethOds: The economic evaluation was conducted in 
two stages: (a) the annual epidemiological effect of the vaccination was assessed at 
steady state with an age-stratified, compartmental dynamic population model cali-
brated on Australian pertussis sero-incidence data, allowing estimation of under-
reporting of pertussis using published notification rates, (b) evaluation of total costs 
and quality adjusted life years (QALYs) associated with pertussis cases using a static 
decision tree model. Two scenarios were compared: the current DTP vaccination 
schedule (2, 4, 6 months; 4 years; 12 years) with and without DTPa-18-month (cov-
erage 83%; effectiveness 88%). Direct medical costs, from a payer perspective, and 
pertussis related QALYs lost were generated via data retrieved from the literature 
and Australian tariffs. A discount rate of 5% was applied to costs and outcomes, and 
a 100-year time horizon used. The pertussis cases, hospitalization, costs and QALYs 
were estimated and compared between strategies. One-way sensitivity analyses 
were conducted on the incremental cost-effectiveness ratio (ICER) by varying key 
parameters. Results: DTPa-18-month was projected to prevent 1.3 million symp-
tomatic pertussis cases; 2,762 hospitalizations; gaining 22,430 QALYs at an increased 
cost of $70,667,758. The predicted ICERs were; $54 per symptomatic pertussis case 
avoided, $3,151 per QALY gained, and $25,590 per hospitalization avoided. Most 
benefit was incurred by the target population, aged < 4 years. Infectiousness level, 
pertussis incidence rate, vaccine cost, administration fee and utility loss for unre-
ported cases were predicted to have the largest effect on the ICER. cOnclusiOns: 
Reintroduction of DTPa-18-month in the Australian NIP was demonstrated to be a 
cost-effective strategy.
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costs were used. Price for sofosbuvir-ledipasvir was the price used in the early access 
program in France. Results: The incremental cost-effectiveness ratio for patient 
treated at F2F3 ranged from 3 000 € / QALY to 20 000 € / QALY for 8 and 12 weeks treat-
ment duration. The sensitivity analyses carried out confirmed the robustness of this 
result. cOnclusiOns: Sofosbuvir-ledipasvir association is a cost-effective treatment 
option for patients with hepatitis C in most clinical contexts.
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ENtErobaCtErIaCEaE IN INtENsIvE CarE uNIts IN hoNg KoNg
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Objectives: The prevalence of carbapenem-resistant Enterobacteriaceae(CRE) has 
been increasing and proactive surveillance is highly recommended. Patients in inten-
sive care unit (ICU) are particularly prone to CRE acquisition due to multiple risk 
factors. The objective of this study was to examine the potential cost and clinical 
outcomes of active CRE surveillance upon ICU admission from the perspective of 
healthcare providers in Hong Kong. MethOds: A Markov model was designed to 
compare the outcomes of active CRE surveillance versus no active surveillance in 
patients admitted to an ICU in Hong Kong. CRE-associated direct medical cost and 
CRE-associated quality-adjusted life years (QALYs) loss were simulated based on the 
model inputs derived from the literature. Sensitivity analyses were conducted to 
evaluate the robustness of the results. Results: In the base-case analysis, active sur-
veillance group showed less QALYs loss (0.3335 vs 0.3827) with higher CRE-associated 
cost (HKD9,825 vs HKD9,800) (USD1= HKD7.8) than control group. The incremental 
cost-effectiveness ratio (ICER) of active surveillance was HKD 500 per QALY saved 
compared to control group. Sensitivity analysis found base-case results robust to 
variation of all model inputs. In 10,000 Monte Carlo simulations, active surveillance 
group was less costly by HKD1,064 per patient (95%CI HKD1,025-1,103; p< 0.001) and 
lower mean QALYs loss by 0.430 (95% CI, 0.422-0.438; p < 0.001) when compared with 
control group. ICERs per QALY saved by the active surveillance group were less than 
the gross domestic product per capita in Hong Kong (HKD330,113) in 99.98% of the 
simulations. cOnclusiOns: Active CRE surveillance upon ICU admission appears to 
be a cost-effective strategy from the perspective of healthcare providers in Hong Kong.
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Objectives: Sofosbuvir (SOF), a new pan-genotypic inhibitor of the hepatitis C 
virus (HCV), has been approved for use in chronic hepatitis C (CHC) patients, 
having shown unprecedented sustained virologic response (SVR) rates and tol-
erability profile. More recently, the combination of SOF and ledipasvir (LDV) – a 
new HCV inhibitor with potent antiviral activity – has resulted in higher rates of 
SVR, especially in genotype-1 HCV. The objective of this analysis was to assess 
the cost-effectiveness of LDV/SOF fixed-dose combination for the treatment of 
HCV genotype-1 in Portugal. MethOds: Cost and effectiveness were based on a 
CHC natural history evolution Markov-type model accounting for the presence 
of cirrhosis and previous treatment experience for genotype-1. The model incor-
porated 5 Metavir score states, 2 SVR states (with and without cirrhosis) and 3 
advanced liver disease states. Results are expressed in incremental costs per life 
year (LY) and quality-adjusted life year (QALY). The choice of comparators was 
based on identical therapeutic indication and financing by the Portuguese National 
Healthcare System (except for SOF which is currently seen as the standard of 
care). Results: Overall LDV/SOF is expected to result in increments between 0.21 
and 6.80 LY (0.26 and 5.80 QALY) depending on the clinical subgroup and compara-
tor, with costs ranging from -56,981€ savings and 23,288€ increment. Incremental 
cost-effectiveness ratios (ICER) varied between LDV/SOF dominance and a maxi-
mum of 10,563€ /LY (9,098€ /QALY). In the comparison against SOF+PegIFN+RBV or 
SOF+RBV, LDV/SOF was shown to be dominant, while versus boceprevir regimens 
ICER varied between 1,896€ /LY (2,597€ /QALY) (experimented cirrhotic) and 10,563€ /
LY (9,098€ /QALY) (experimented non-cirrhotic). When LDV/SOF was compared 
against PegIFN+RBV, the ICER variation was 3,828€ /LY (5,396€ /QALY) (naïve cir-
rhotic) to 8,042€ /LY (6,776€ /QALY) (experimented non-cirrhotic). cOnclusiOns: 
Ledipasvir/sofosbuvir is expected to represent good value for money including 
cost-saving scenarios in the treatment of CHC genotype-1 in Portugal, irrespective 
of the clinical subgroup or comparator.
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rECtal CulturE tEstINg bEforE traNsrECtal ultrasouNd-guIdEd 
ProstatE bIoPsY (trusbx) IN hoNg KoNg – a Cost-EffECtIvENEss 
aNalYsIs
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The Chinese University of Hong Kong, Shatin, Hong Kong
Objectives: Rectal culture-guided antibiotic prophylaxis is an effective strategy 
in preventing post-TRUSBx infections. This study aimed to examine the cost-effec-
tiveness of pre-biopsy rectal swab culture-guided antibiotic prophylaxis in patients 
undergoing TRUSBx from the societal perspective in Hong Kong. MethOds: A deci-
sion tree model was designed to compare clinical outcomes and cost of TRUSBx with 
rectal culture-guided versus empirical antibiotic prophylaxis in a hypothetical cohort 
caspofungin. The cost of achieving one more patient successfully treated with anid-
ulafungin, caspofungin, and micafungin compared to fluconazole was € 17,199, € 
23,962, and € 27,339, respectively. The result remained stable despite modification 
of the duration of the first-line and second-line treatments, as well as most of the 
dosing regimens. The probabilistic analysis also remained stable. cOnclusiOns: 
According to the model, anidulafungin produced savings and was the dominant 
treatment compared with micafungin and caspofungin in non-neutropenic adult 
patients with candidemia and/or invasive candidiasis in ICUs in Spain.
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uNdEr 5 YEars of agE IN sWItZErlaNd
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Objectives: Rotavirus (RV) infection is a leading cause of severe diarrhoea among 
young children in Switzerland and it is associated with a significant financial 
burden. Two RV vaccines are marketed globally, but only RIX4414 is licensed in 
Switzerland. This study aims to evaluate the cost-effectiveness of RV vaccination 
with RIX4414 among children less than 5 years of age in Switzerland. MethOds: A 
previously published age-compartmental Markov cohort model with monthly cycles 
was used to evaluate the RV events and the associated health outcomes and costs 
over the first 5 years of a new-born cohort. It compared the RV burden in a cohort of 
84,823 new-borns with or without RIX4414. Transition probabilities, vaccine efficacy, 
Quality-Adjusted-Life-Years (QALY), Swiss specific incidence and costs data were 
obtained from literature or official reports. Retail vaccine price of CHF61.60 per 
dose was used. Incremental cost-effectiveness ratio (ICER) was calculated under 
a payer’s perspective. Extensive sensitivity analyses were also performed to test 
the robustness of the results. Results: The vaccination programme with RIX4414 
at 90% coverage rate would prevent 1,411 hospitalisation (88%), 145 nosocomial 
infections (63%), 3,914 emergency room visits (88%), 13,006 medical visits (87%) and 
27,861 (70%) RV events. From a payer’s perspective, the vaccine cost completely offset 
the direct RV medical cost and vaccination may offer 39 extra QALYs. Sensitivity 
analyses showed that the frequency of medical visits, of RV events and the cost of 
hospitalisation were the key drivers influencing the results. cOnclusiOns: RV 
vaccination programme with RIX4414 could reduce substantially the number of RV 
cases. The vaccine cost offsets the total direct medical costs.
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Objectives: In the European context, the nonavalent HPV vaccine 
(6/11/16/18/31/33/45/52/58) expands the spectrum of prevention from 75% to 89% 
of HPV-positive cancer cases and from 47% to 82% of precancerous lesions in the cer-
vix, vulva, vagina and anus. This analysis aims to estimate the public health impact 
and the incremental cost-effectiveness of a universal (girls and boys) vaccination 
program with a nonavalent HPV vaccine as compared to the current universal vacci-
nation program with a quadrivalent HPV vaccine (6/11/16/18), in Austria. MethOds: 
A dynamic transmission model including a wide range of health and cost out-
comes related to cervical, anal, vulvar, vaginal diseases and genital warts was 
calibrated to Austrian epidemiological data. The clinical impact due to the 5 new 
types was included for cervical diseases only, producing conservative outcomes. In 
the base case, a two-dose schedule, lifelong vaccine type-specific protection and 
a vaccination coverage rate of 60% and 40% for girls and boys respectively for the 
9-year old cohorts were assumed. A threshold of € 30,000/QALY-gained was consid-
ered. Results: Universal vaccination with the nonavalent vaccine was shown to 
be having the potential to reduce the incidence of HPV16/18/31/33/45/52/58 -related 
cervical cancer by 92% and the related CIN2/3 by 96% after 100 years, relative to 75% 
and 76% with the quadrivalent vaccine respectively. Furthermore, the nonavalent 
vaccine was projected to prevent an additional of 8,281 cases of CIN1, 14,893 cases 
of CIN2/3 and 2,544 cases of cervical cancer, over 100 years. Finally, the base case 
analysis resulted into an ICER of approximately € 16,441. cOnclusiOns: The find-
ings of the analysis indicate that universal vaccination with a nonavalent vaccine 
in Austria is estimated to be cost-effective when compared to the quadrivalent 
vaccine across a range of sensitivity analyses and, further reduce the public health 
burden of HPV-related cancers and diseases.
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Objectives: In France, 190,306 patients were suffering from chronic hepatitis C in 
2012. These patients have a decreased life expectancy and are susceptible to complica-
tions associated with chronic hepatitis. The association of Ledipasvir and Sofosbuvir, 
an interferon-free treatment, has demonstrated in several phase III trials sustained 
viral response (SVR) rates close to a 100% for genotype 1 (G1) and 4 (G4) patients in 
8 to 12 weeks. The objective of this study was to compare the cost-effectiveness of 
using this association in the treatment of chronic HCV infection in multiple clinical 
context including past treatment (naïve or experience), coinfection, cirrhosis and 
stage at treatment initiation. MethOds: A Markov model was used to assess the cost-
effectiveness of sofosbuvir-ledipasvir association compare to every available current 
and upcoming strategy. The model simulated the natural history of HCV infection 
from F0 to F4 taking into account the characteristics of the patients at treatment. To 
be conservative, the model also included fibrosis progression for SVR patients. SVR 
rates for F0 to F4 were based on data from clinical trials. Utilities associated with dif-
ferent stages of disease were based on data from the literature. French direct medical 
